Tyra Biosciences, Inc. (TYRA): Depreciation & Amortization
$546.0K
Year ended 2025-12-31
$539.0K
Trailing 12 months to 2026-06-30
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $546.0K | +5.2% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $519.0K | +45.4% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $357.0K | n/c | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $296.0K | +111.4% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $140.0K | +197.9% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $47.0K | n/a | 2022-03-03, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $546.0K | +5.2% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $4.59M | +96.3% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $4.05M | -36.5% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $1.03M | -76.6% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $2.17M | +0.7% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Neurogene Inc. (NGNE) | 2025-12-31 | $3.04M | -4.8% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $323.0K | +25.2% |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | 2025-12-31 | $739.0K | -42.7% |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗